SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market weighs potential near-term rate cuts against longer-term economic concerns and Japan bond yield surge. Community members are actively discussing whether the recent AI-driven rally is sustainable, pointing to specific levels and potential downside risks, while some are anticipating a year-end rally.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions about its AI strategy, particularly the AWS re:Invent conference and new AI chip developments that are intended to compete with Nvidia. The community is weighing the potential impact of these innovations on Amazon's market position and profitability, along with its ongoing partnerships. Some are concerned over high spending and performance, while others express optimism about long-term cloud and AI growth.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

Polyrizon is trending due to positive preclinical data regarding its intranasal Naloxone hydrogel, with the community focusing on its potential as a multi-day runner and comparing it to other low-float Israeli stocks like $SMX. Discussions include potential price targets and the possibility of a short squeeze, while some traders are wary of potential dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid discussions of potential catalysts like upcoming earnings and speculation around key figures like Roaring Kitty and Michael Burry. The community is actively dissecting trading patterns, potential gamma ramps, and the impact of large buy orders, while also eyeing the performance of GME warrants. Some traders express frustration with persistent price suppression despite positive fundamentals and potential short squeezes.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions about its recent earnings beat and future prospects in the AI automation space; the community is weighing in on whether the company can sustain growth and capitalize on its partnerships with major tech players. Some traders are highlighting the high short interest and potential for a squeeze, while others focus on long-term potential and the stock's undervaluation relative to its peers. Discussions also include the upcoming fireside chat at the Barclays Global Technology Conference.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Global X Dow 30 Covered Call ETF ($DJIA) is trending as investors weigh the impact of recent jobs data and potential Federal Reserve interest rate cuts. Community members are actively discussing resistance and support levels, with some anticipating a continued bullish trend while others warn of overbought conditions and an impending market correction. Hedge alerts are circulating, offering put options as protection against potential downturns.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid community discussions around its AI strategy and recent earnings expectations, with some questioning its ability to capitalize on AI, while others highlight its solid fundamentals. The stock's underperformance compared to its peers is also a key talking point, with some expressing concerns about the company's leadership. Upcoming earnings are a major catalyst, with potential for significant price movement based on the company's AI initiatives.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 2x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders weigh market volatility amid economic data and global events. Community members are actively discussing potential market corrections, hedging strategies, and the impact of quantitative tightening. The upcoming reverse split is also a key point of discussion, with some traders expressing concerns about its impact on options.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

BRK.B is trending amid discussion of its massive cash reserves and strong Q3 earnings, with operating profits surging. Community chatter revolves around Berkshire's strategy given the current market conditions, particularly regarding potential acquisitions or share buybacks. Some investors view BRK.B as a safe haven during market uncertainty, while others question its valuation and future performance post-Buffett.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as the Fusaka upgrade goes live, promising improved scalability and reduced Layer 2 transaction fees, sparking excitement among bulls. Community members are closely watching for a potential "sell the news" event, while others anticipate a significant price surge. Broader discussions include institutional adoption and the potential for ETH to outperform BTC in the coming cycle.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer

Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer PR Newswire MORRISTOWN, N.J., Dec. 1, 2025...

Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire...

Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London

Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London PR Newswire MORRISTOWN...

What is HC Wainwright's Estimate for WHWK FY2025 Earnings?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Whitehawk Therapeutics in a note issued to investors on...

Whitehawk Therapeutics (NASDAQ:WHWK) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus...

Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights PR Newswire...

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC Whitehawk Therapeutics Presents Real-World...

Tempus AI Fuels Growth Through Strategic Biotech Collaborations

TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.

Healthtech company Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK) on Thursday, aimed at developing the latter’s cancer treatment pipeline.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tempus.com/news/pr/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research/">deal</a>, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including a de-identified multimodal database, to support its clinical trial designs. A de-identified multimodal database is a collection of diverse datasets, such as medical images, clinical notes, and genetic information, from which all personally identifiable information or protected health information has been removed. It is expected that Tempus’ dataset will help Whitehawk focus on the right patient population.Whitehawk’s antibody drug conjugate portfolio includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers. The collaboration is aimed at advancing research centered on these candidates.“By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline,” said Whitehawk CEO Dave Lennon.<a href="https://stocktwits.com/symbol/WHWK">Whitehawk shares</a> soared 23% on Thursday afternoon at the time of writing, while <a href="https://stocktwits.com/symbol/TEM">Tempus shares</a> dropped about 0.5%.On Stocktwits, retail sentiment around WHWK jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:590/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_26_39_PM_png_87d1a96f13.webp" alt="WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="590" height="61"><figcaption>WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>Retail sentiment around TEM, however, stayed within the ‘bearish’ territory, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:591/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_29_47_PM_png_cc45006531.webp" alt="TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="591" height="61"><figcaption>TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user hopes WHWK rallies into the $4 to $5 range.<stembedurl>https://stocktwits.com/cjstocksup/message/632578934</stembedurl>Another sounded optimistic for TEM stock, citing its relationships with big pharma and strong backlog.<stembedurl>https://stocktwits.com/TICKERTUTOR/message/632569480</stembedurl>WHWK stock has dropped 18% this year, while TEM shares rose 171% during the period.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-rises-after-launch-of-generic-cholestrol-lowering-drug-by-canadian-unit/ch6p4DqR3nu">Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Whitehawk Therapeutics Stock Rallies 25% On Tempus AI Collaboration Deal: Retail Hopes For A Rally Toward $5 Mark

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.

Equity

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.


Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ...

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.69	--	--	N/A
Q3 '25	-$0.51	-$0.26	49.02%	BEAT
Q2 '25	$0.82	-$0.76	-192.12%	MISSED
Q1 '25	--	$1.83	--	N/A

WHWK
Whitehawk Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest WHWK News

WHWKWhitehawk Therapeutics Inc.